X

Trial Profile

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Biomarker; Therapeutic Use
Acronyms ENACT
Sponsors Astellas Pharma

Most Recent Events

06 Jun 2023 Results assessing transcriptomic changes over time for men undergoing AS and those treated transiently with ENZA presented at the 59th Annual Meeting of the American Society of Clinical Oncology
25 May 2023 Results presented in the Veracyte inc Media Release.
25 May 2023 According to a Veracyte media release, data from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com